Early complications after intraoperative radiotherapy revisited

Holmes, Dennis R.

doi:10.1002/jso.24590

Cited by 3 publications

(4 citation statements)

References 5 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results suggest that depending on the size of spherical applicator chosen, patients would receive differing doses. For reference, the average applicator radius used in the TARGIT‐A trial was 17.5–20.0 mm …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

An investigation into the INTRABEAM miniature x‐ray source dosimetry using ionization chamber and radiochromic film measurements

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…For reference, the average applicator radius used in the TARGIT-A trial was 17.5-20.0 mm. 40 While our results investigated the dosimetry for the bare source (i.e., no applicator), one could estimate the effect of the presence of a spherical applicator. The depth dose measurements shown in Fig.…”

Section: Discussionmentioning

confidence: 99%

An investigation into the INTRABEAM miniature x‐ray source dosimetry using ionization chamber and radiochromic film measurements

et al. 2018

View full text Add to dashboard Cite

show abstract

“…As the distance of the breast skin from the surface of the APs increases, the DERs further decrease. During breast cancer treatment with an INTRABEAM ® IORT system used after breast-conserving surgery, breast skin injury is probable due to backscatter radiation (Holmes 2017). However, the presence of Au NPs in the breast tissue (tumor bed) leads to an increased Z eff of the breast tissue (tumor bed), which in return increases photoelectric absorption after irradiating with a 50-kV INTRABEAM ® source.…”

Section: Discussionmentioning

confidence: 99%

Gold-nanoparticle-enriched breast tissue in breast cancer treatment using the INTRABEAM® system: a Monte Carlo study

Tegaw

Geraily

Gholami

et al. 2021

Radiat Environ Biophys

View full text Add to dashboard Cite

Using a 50-kV INTRABEAM ® system after breast-conserving surgery, breast skin injury and long treatment time remain the challenging problems when large-size spherical applicators are used. This study has aimed to address these problems using gold (Au) nanoparticles (NPs). For this, surface and isotropic doses were measured using a Gafchromic EBT3 film and a water phantom. The particle propagation code EGSnrc/Epp was used to score the corresponding doses using a geometry similar to that used in the measurements. The simulation was validated using a gamma index of 2%/2 mm acceptance criterion in the gamma analysis. After validation Au-NP-enriched breast tissue was simulated to quantify any breast skin dose reduction and shortening of treatment time. It turned out that the gamma value deduced for validation of the simulation was in an acceptable range (i.e., less than one). For 20 mg-Au/g-breast tissue, the calculated Dose Enhancement Ratio (DER) of the breast skin was 0.412 and 0.414 using applicators with diameters of 1.5 cm and 5 cm, respectively. The corresponding treatment times were shortened by 72.22% and 72.30% at 20 mg-Au/g-breast tissue concentration, respectively. It is concluded that Au-NP-enriched breast tissue shows significant advantages, such as reducing the radiation dose received by the breast skin as well as shortening the treatment time. Additionally, the DERs were not significantly dependent on the size of the applicators.

show abstract

“…In general, IORT recipients exercise the same follow‐up protocol as patients treated with WBI, including routine post‐operative follow‐up visits with the surgeon, radiation oncologist, and medical oncologist. Clinical examination should exclude the presence of a symptomatic seroma, which might benefit from aspiration, and document any potential complications of radiotherapy and/or surgery, including cellulitis, radiation dermatitis, fibrosis, telangiectasia, and wound dehiscence . However, with the exception of recurrent seromas (2.1% TARGIT vs 0.8% WBI, P = 0.012) and grade III/IV fibrosis (0.5% TARGIT vs 2.1% WBI, P = 0.002), the TARGIT‐A trial revealed no significant difference between TARGIT and WBI in the rate of infection, hematoma, skin breakdown, or delayed wound healing 1 .…”

Section: Patient Follow‐upmentioning

confidence: 99%

Intraoperative radiotherapy: Patient selection, management, and follow‐up

Holmes

Zimmerman²

2017

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

Intraoperative partial breast radiotherapy is an alternative or an adjunct to fractionated whole breast irradiation for the administration of adjuvant radiotherapy in breast cancer following breast conserving surgery. Establishing intraoperative radiotherapy as a therapeutic modality requires a multidisciplinary approach to patient selection, workup, surgery, radiation protocols, chemotherapy, and patient follow up. In this article, we review the published evidence for best clinical practice, as a guide to the introduction of intraoperative radiotherapy for breast cancer treatment.

show abstract

Early complications after intraoperative radiotherapy revisited

Cited by 3 publications

References 5 publications

An investigation into the INTRABEAM miniature x‐ray source dosimetry using ionization chamber and radiochromic film measurements

An investigation into the INTRABEAM miniature x‐ray source dosimetry using ionization chamber and radiochromic film measurements

Gold-nanoparticle-enriched breast tissue in breast cancer treatment using the INTRABEAM® system: a Monte Carlo study

Intraoperative radiotherapy: Patient selection, management, and follow‐up

Contact Info

Product

Resources

About